Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Transfer of Channel common stock and Series C Preferred Stock held by Chromocell Holdings to AWI in satisfaction of a default judgment.
Rescission of 111,129 shares of Common Stock held by affiliates of the Representative, with refund of consideration.
Assignment to Ligand of LNHC's material assets and liabilities relating to the NITRICIL platform technology and ZELSUVMI.
Exclusive license and sublicense of ZELSUVMI rights, with 13% royalty and milestone payments to Ligand.
Master Services Agreement under which LNHC provides development and manufacturing services to Ligand Parties.
Revolving bridge promissory note under which Ligand loaned cash and settled LNHC expenses; maximum borrowing stated.
Purchase of Series A Preferred Stock in the PIPE Financing.
Sale to NRV of the Company's rights to a portion of ZELSUVMI revenue payments, with royalty terms.
Purchase of a portion of Channel Covered Products revenue rights and related royalty and sublicensing rights.
Purchase of a Convertible Note in the Convertible Note Financing.
Purchase of a Convertible Note in the Convertible Note Financing.
Loading...
